Oppenheimer & Co. Inc. Buys 16,871 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Oppenheimer & Co. Inc. increased its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 43.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,287 shares of the biotechnology company's stock after acquiring an additional 16,871 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in ADMA Biologics were worth $1,097,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ADMA. Mark Sheptoff Financial Planning LLC bought a new position in shares of ADMA Biologics in the fourth quarter valued at approximately $35,000. Vision Financial Markets LLC bought a new stake in ADMA Biologics during the fourth quarter valued at approximately $51,000. Farther Finance Advisors LLC lifted its position in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares during the last quarter. AlphaQuest LLC bought a new stake in ADMA Biologics during the fourth quarter valued at approximately $84,000. Finally, GF Fund Management CO. LTD. bought a new stake in ADMA Biologics during the fourth quarter valued at approximately $85,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.24 during trading hours on Friday, hitting $18.16. 4,944,670 shares of the company's stock were exchanged, compared to its average volume of 3,698,999. The company has a market capitalization of $4.34 billion, a PE ratio of 21.36 and a beta of 0.47. ADMA Biologics Inc has a 12-month low of $10.21 and a 12-month high of $25.67. The business's 50 day simple moving average is $20.57 and its 200-day simple moving average is $18.74. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. During the same period last year, the business posted $0.08 earnings per share. The company's revenue was up 40.2% compared to the same quarter last year. On average, equities research analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 7,779 shares of ADMA Biologics stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the transaction, the director now directly owns 114,830 shares of the company's stock, valued at $2,333,345.60. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director now directly owns 87,330 shares in the company, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock valued at $9,644,269 over the last three months. 3.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ADMA shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Raymond James Financial lifted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.